Prof. Song Qu 曲颂
Chief Physician, Professor
Department of Radiation Oncology, Guangxi Medical University Cancer Hospital, Nanning
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Radiation therapy for nasopharyngeal cancer, head and neck tumors, liver cancer, rectal cancer, urologic tumors, lymphoma, and breast cancer.
Dr. Qu holds a PhD in oncology and serves as Chief Physician, Professor, and Director of the Third Ward of the Radiation Oncology Department. Dr. Qu is the chief expert for head and neck tumors and supervises doctoral and master’s students. From 2014 to 2015, Dr. Qu was a visiting scholar in the Department of Radiation Oncology at UCSF Medical Center.
Professional roles
- Standing Committee Member, Nasopharyngeal Cancer Professional Committee, China Anti-Cancer Association
- Chair, Nasopharyngeal Cancer Professional Committee, Guangxi Anti-Cancer Association
- Member, Head and Neck Tumor Expert Committee, Chinese Society of Clinical Oncology (CSCO)
- Editorial Board Member, Chinese Journal of Cancer
Name order: in Chinese the family name comes first (Qu Song). Papers usually list the name as Song Qu or Qu S.
Selected publications
69 papers on PubMed matched by name and affiliation; 17 as first or senior author since 2016. Most recent first- or senior-author papers:
- Biochim Biophys Acta Mol Basis Dis, 2026 (senior author): Extracellular vesicles in tumor immune escape and therapeutic resistance: mechanisms and immunopharmacological opportunities. PubMed 42107808
- J Transl Med, 2026 (senior author): EV-transferred miR-7111-3p inhibits malignant phenotypes and tumor growth in nasopharyngeal carcinoma via targeting APP-regulated epithelial-mesenchymal transition. PubMed 42706553
- iScience, 2026 (senior author): MiR-1202 increases radioresistance in nasopharyngeal carcinoma by targeting NAIF1/MAPK/ERK pathway. PubMed 41952979
- Biomolecules, 2026 (senior author): Extracellular Vesicles: A Multidimensional Role in the Occurrence and Development of Nasopharyngeal Carcinoma. PubMed 41750341
- J Inflamm Res, 2026 (senior author): Development and Validation of a Neutrophil Percentage-to-Albumin Ratio-Based Nomogram for Predicting Overall Survival in Locally Advanced Nasopharyngeal Carcinoma. PubMed 41890818
- Cancer, 2026 (senior author): Toripalimab plus concurrent chemoradiotherapy for recurrent nasopharyngeal carcinoma: A single-arm, phase 2 clinical trial. PubMed 41548086
- Front Nutr, 2025 (senior author): Comparative study on the predictive value of TyG, TyG-BMI, and TG/HDL-C for progression-free survival in patients with locally advanced nasopharyngeal carcinoma. PubMed 41019567
- Int J Cancer, 2025 (senior author): Efficacy and safety of Anlotinib in combination with gemcitabine and cisplatin as a first-line treatment for recurrent or metastatic nasopharyngeal carcinoma: A single-arm clinical trial. PubMed 39825777
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital. This name is shared by other researchers, so we checked that most papers list this doctor's hospital and department.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion